{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:30:21Z","timestamp":1786696221611,"version":"build-2736575974"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-1647_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Accurate B-lineage assignment in acute leukemia is critical for therapeutic decisions. While nuclear expression of PAX5 protein (nPAX5) is a highly reliable marker for B-cell differentiation, its conventional assessment by time-consuming immunohistochemistry (IHC) is not ideal for rapid diagnosis. This study aimed to validate the utility of flow cytometric (FCM) detection of nPAX5 for the diagnosis of B-lymphoblastic leukemia (B-ALL), potentially enhancing diagnostic efficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1647_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted, comparing nPAX5 expression by FCM and IHC in 125 bone marrow biopsies (57\u00a0B-ALL, 12\u00a0T-ALL, 56 AML). Further diagnostic performance analysis, using ROC analysis of the geometric mean fluorescence intensity ratio (Blast\/Normal T-cell), was performed for nPAX5, cCD22, and cCD79a across a larger cohort of 538 acute leukemia cases (123\u00a0B-ALL, 29\u00a0T-ALL, 386\u00a0AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1647_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FCM and IHC for PAX5 expression showed 100\u202f% concordance across the 125 cases (57\/57\u00a0B-ALL positive; 0\/12\u00a0T-ALL negative). The single PAX5-positive AML case harbored the t(8;21) translocation. ROC analysis demonstrated excellent diagnostic performance for both cCD79a (AUC 0.980) and nPAX5 (AUC 0.955). At optimal criteria, cCD79a achieved 100.00\u202f% specificity and 91.06\u202f% sensitivity. nPAX5 showed strong utility, matching the 91.06\u202f% sensitivity with 89.45\u202f% specificity (criterion &gt;6.30). cCD22 exhibited moderate discriminatory power (AUC 0.807).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-1647_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Flow cytometric nuclear PAX5 (nPAX5) demonstrated 100\u202f% agreement with IHC and exhibited excellent diagnostic accuracy (AUC 0.955, 91.06\u202f% sensitivity). These compelling results validate nPAX5 as a reliable and powerful FCM marker, supporting its immediate adoption for rapid and efficient B-lineage assignment in acute leukemia diagnostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-1647","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:59:47Z","timestamp":1769497187000},"page":"1432-1437","source":"Crossref","is-referenced-by-count":0,"title":["Utility of flow cytometric PAX5 protein detection for the diagnosis of B-cell acute lymphoblastic leukemia"],"prefix":"10.1515","volume":"64","author":[{"given":"Tanintorn","family":"Pootrakul","sequence":"first","affiliation":[{"name":"Saraburi Hospital , Saraburi , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burana","family":"Khiankaew","sequence":"additional","affiliation":[{"name":"Department of Pathology , 26687 Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paisarn","family":"Boonsakan","sequence":"additional","affiliation":[{"name":"Department of Pathology , 26687 Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Paisooksantivatana","sequence":"additional","affiliation":[{"name":"Department of Pathology , 26687 Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026081408005211282_j_cclm-2025-1647_ref_001","unstructured":"Shah, B, Mattison, RJ, Abboud, R, Aldoss, I, Badar, T, Bhaskar, S, et al.. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 2.2025 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 [cited 2025 Dec 11]. Available from: https:\/\/www.nccn.org."},{"key":"2026081408005211282_j_cclm-2025-1647_ref_002","doi-asserted-by":"crossref","unstructured":"Li, L, Zhang, D, Cao, X. EBF1, PAX5, and MYC: regulation on B\u00a0cell development and association with hematologic neoplasms. Front Immunol 2024;15:1320689. https:\/\/doi.org\/10.3389\/fimmu.2024.1320689.","DOI":"10.3389\/fimmu.2024.1320689"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_003","doi-asserted-by":"crossref","unstructured":"Medvedovic, J, Ebert, A, Tagoh, H, Busslinger, M. Pax5: a master regulator of B\u00a0cell development and leukemogenesis. Adv Immunol 2011;111:179\u2013206. https:\/\/doi.org\/10.1016\/B978-0-12-385991-4.00005-2.","DOI":"10.1016\/B978-0-12-385991-4.00005-2"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_004","doi-asserted-by":"crossref","unstructured":"Jia, Z, Gu, Z. PAX5 alterations in B-cell acute lymphoblastic leukemia. Front Oncol 2022;12:1023606. https:\/\/doi.org\/10.3389\/fonc.2022.1023606.","DOI":"10.3389\/fonc.2022.1023606"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_005","doi-asserted-by":"crossref","unstructured":"Tiacci, E, Pileri, S, Orleth, A, Pacini, R, Tabarrini, A, Frenguelli, F, et al.. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia [Internet]. Cancer Res 2004;64.","DOI":"10.1158\/0008-5472.CAN-04-1865"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_006","doi-asserted-by":"crossref","unstructured":"Hidalgo Cedeno, EF, Germans, S, Pan, Z, Mendez, L, Weinberg, OK, Xu, ML. PAX5 as a diagnostic tool in unconventional acute leukemia: establishing immunohistochemical evidence of B-cell lineage. Hum Pathol 2025;163:105903.","DOI":"10.1016\/j.humpath.2025.105903"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_007","doi-asserted-by":"crossref","unstructured":"Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, et al.. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","DOI":"10.1182\/blood.2022015850"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_008","doi-asserted-by":"crossref","unstructured":"Zwollo, P, Haines, A, Rosato, P, Gumulak-Smith, J. Molecular and cellular analysis of B-cell populations in the rainbow trout using Pax5 and immunoglobulin markers. Dev Comp Immunol 2008;32:1482\u201396. https:\/\/doi.org\/10.1016\/j.dci.2008.06.008.","DOI":"10.1016\/j.dci.2008.06.008"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_009","doi-asserted-by":"crossref","unstructured":"Holl, E, Kapinsky, M, Larbi, A. An update on flow cytometry analysis of hematological malignancies: focus on standardization. Cancers 2025;17:2045. https:\/\/doi.org\/10.3390\/cancers17122045.","DOI":"10.3390\/cancers17122045"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_010","doi-asserted-by":"crossref","unstructured":"Devitt, KA, Oldaker, T, Shah, K, Illingworth, A. Summary of validation considerations with real-life examples using both qualitative and semiquantitative flow cytometry assays. Cytometry B Clin Cytom 2023;104:374\u201391. https:\/\/doi.org\/10.1002\/cyto.b.22123.","DOI":"10.1002\/cyto.b.22123"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_011","unstructured":"Clinical and Laboratory Standards Institute. Validation of assays performed by flow cytometry. 1st ed. CLSI guideline H62. Wayne (PA): Clinical and Laboratory Standards Institute; 2021."},{"key":"2026081408005211282_j_cclm-2025-1647_ref_012","doi-asserted-by":"crossref","unstructured":"Marsman, C, Jorritsma, T, Brinke, AT, Marieke van Ham, S. Flow cytometric methods for the detection of intracellular signaling proteins and transcription factors reveal heterogeneity in differentiating human B\u00a0cell subsets. Cells 2020;9.","DOI":"10.20944\/preprints202012.0028.v1"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_013","doi-asserted-by":"crossref","unstructured":"Valbuena, JR, Medeiros, LJ, Rassidakis, GZ, Hao, S, Wu, CD, Chen, L, et al.. Expression of B cell-specific activator protein\/PAX5 in acute myeloid\u00a0leukemia with t(8;21)(q22;q22). Am J Clin Pathol 2006;126:235\u201340. https:\/\/doi.org\/10.1309\/lg0q-0vxy-betj-4vhe.","DOI":"10.1309\/LG0Q0VXYBETJ4VHE"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_014","doi-asserted-by":"crossref","unstructured":"Ray, D, Kwon, SY, Tagoh, H, Heidenreich, O, Ptasinska, A, Bonifer, C. Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression. Blood 2013;122:759\u201369. https:\/\/doi.org\/10.1182\/blood-2013-02-482497.","DOI":"10.1182\/blood-2013-02-482497"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_015","unstructured":"WHO Classification of Tumours Editorial Board. WHO classification of tumours of haematolymphoid tumours, 5th ed. Lyon: International Agency for Research on Cancer; 2024."},{"key":"2026081408005211282_j_cclm-2025-1647_ref_016","doi-asserted-by":"crossref","unstructured":"Jensen, KC, Higgins, JPT, Montgomery, K, Kaygusuz, G, Van De Rijn, M, Natkunam, Y. The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Mod Pathol 2007;20:871\u20137. https:\/\/doi.org\/10.1038\/modpathol.3800831.","DOI":"10.1038\/modpathol.3800831"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_017","unstructured":"Kolhe, R, Reid, MD, Lee, JR, Cohen, C, Ramalingam, P. Immunohistochemical expression of PAX5 and TdT by merkel cell carcinoma and pulmonary small cell carcinoma: a potential diagnostic pitfall but useful discriminatory marker [Internet]. Int J Clin Exp Pathol 2013;6."},{"key":"2026081408005211282_j_cclm-2025-1647_ref_018","doi-asserted-by":"crossref","unstructured":"Pan, Z, Chen, YY, Wu, X, Trisal, V, Wilczynski, SP, Weiss, LM, et al.. Merkel cell carcinoma of lymph node with unknown primary has a significantly lower association with merkel cell polyomavirus than its cutaneous counterpart. Mod Pathol 2014;27:1182\u201392. https:\/\/doi.org\/10.1038\/modpathol.2013.250.","DOI":"10.1038\/modpathol.2013.250"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_019","doi-asserted-by":"crossref","unstructured":"Chteinberg, E, Kolarova, J, Vogt, J, Macamo, A, Bormann, F, Kretzmer, H, et al.. The significance of PAX5 in merkel cell carcinoma. J\u00a0Pathol 2025;266:81\u201394. https:\/\/doi.org\/10.1002\/path.6410.","DOI":"10.1002\/path.6410"},{"key":"2026081408005211282_j_cclm-2025-1647_ref_020","doi-asserted-by":"crossref","unstructured":"Bommannan, BKK, Arumugam, JR, Sundersingh, S, Rajan, PT, Radhakrishnan, V, Sagar, TG. CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era. Leuk Lymphoma 2019;60:3154\u201360. https:\/\/doi.org\/10.1080\/10428194.2019.1625043.","DOI":"10.1080\/10428194.2019.1625043"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1647\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:05:36Z","timestamp":1786694736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-1647\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,5,26]]}},"alternative-id":["10.1515\/cclm-2025-1647"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-1647","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}